尼泊尔局部用0.2%氯己定与5%那他霉素治疗真菌性角膜炎:随机对照非劣效性试验
在尼泊尔一家三级眼科医院开展的随机对照单盲非劣效性试验,纳入354例涂片或共聚焦显微镜确诊的丝状真菌角膜炎成人患者,比较局部0.2%氯己定与5%那他霉素。结果显示氯己定未达到非劣效,那他霉素组3个月最佳眼镜矫正视力(BSCVA)显著更优、角膜穿孔或治疗性角膜移植更少。
要点
- 氯己定未显示对那他霉素的非劣效性,校正基线BSCVA后那他霉素组3个月BSCVA显著更优(回归系数-0.30)。
- 氯己定组穿孔或急诊角膜移植24/175(13.7%)多于那他霉素组10/173(5.8%),P=0.018。
- 作者结论认为那他霉素仍是丝状真菌角膜炎首选的一线单药治疗。
核心结论
- 局部0.2%氯己定未达到对5%那他霉素的非劣效性,那他霉素治疗与显著更好的视力和更少不良事件相关。
- 作者结论:那他霉素仍是丝状真菌角膜炎首选的一线单药治疗。
研究设计与样本
- 随机对照、单盲、非劣效性临床试验,在尼泊尔一家三级眼科医院开展。
- 纳入涂片或共聚焦显微镜确诊丝状真菌感染的成人;混合真菌-细菌感染从主要分析中排除,但纳入次要分析和次要安全性结局。
- 2019年6月3日至2020年11月9日共入组354例合格受试者,随机分配至氯己定组178例、那他霉素组176例。
- 主要分析为意向性分析,采用线性回归,以基线最小分辨角对数(logMAR)最佳眼镜矫正视力(BSCVA)和治疗分组为预设协变量;非劣效界值为0.15 logMAR。
- 试验注册号ISRCTN14332621。
主要发现
- 氯己定组153例、那他霉素组151例有主要结局数据;其中混合细菌-真菌感染20例(氯己定12/153、那他霉素8/151),从主要分析中排除,最终284例纳入主要结局评估(氯己定141例、那他霉素143例)。
- 未发现氯己定非劣于那他霉素的证据,校正基线BSCVA后那他霉素组3个月BSCVA显著优于氯己定组(回归系数-0.30;95%CI,-0.42至-0.18;P<0.001)。
- 氯己定组穿孔和急诊角膜移植24/175(13.7%)多于那他霉素组10/173(5.8%)(P=0.018,含混合感染)。
- 校正基线溃疡深度后,那他霉素组发生穿孔或需急诊角膜移植的可能性更低(比值比0.34;95%CI,0.15-0.79;P=0.013)。
关键数值与推荐
- 主要结局为3个月时BSCVA;次要结局包括90天内穿孔或治疗性穿透性角膜移植。
- 非劣效界值为0.15 logMAR。
临床怎么用
- 作者结论认为那他霉素仍是丝状真菌角膜炎首选的一线单药治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate if topical chlorhexidine 0.2%, which is low cost and easy to formulate, is noninferior to topical natamycin 5% for the treatment of filamentous fungal keratitis. DESIGN: Randomized controlled, single-masked, noninferiority clinical trial. PARTICIPANTS: Adults attending a tertiary-level ophthalmic hospital in Nepal with filamentous fungal infection confirmed on smear or confocal microscopy. METHODS: Participants were randomly allocated to receive topical chlorhexidine 0.2% or topical natamycin 5%. Primary analysis (intention-to-treat) was by linear regression, using baseline logarithm of the minimum angle of resolution (logMAR) best spectacle-corrected visual acuity (BSCVA) and treatment arm as prespecified covariates. Mixed fungal-bacterial infections were excluded from the primary analysis but included in secondary analyses and secondary safety-related outcomes. The noninferiority margin was 0.15 logMAR. This trial was registered with ISRCTN, number ISRCTN14332621. MAIN OUTCOME MEASURES: The primary outcome measure was BSCVA at 3 months. Secondary outcome measures included perforation or therapeutic penetrating keratoplasty by 90 days. RESULTS: Between June 3, 2019, and November 9, 2020, 354 eligible participants were enrolled and randomly assigned: 178 to chlorhexidine and 176 to natamycin. Primary outcome data were available for 153 and 151 of the chlorhexidine and natamycin groups, respectively. Of these, mixed bacterial-fungal infections were found in 20 cases (12/153 chlorhexidine, 8/151 natamycin) and excluded from the primary analysis. Therefore, 284 patients were assessed for the primary outcome (141 chlorhexidine, 143 natamycin). We did not find evidence to suggest chlorhexidine was noninferior to natamycin and in fact found strong evidence to suggest that natamycin-treated participants had significantly better 3-month BSCVA than chlorhexidine-treated participants, after adjusting for baseline BSCVA (regression coefficient, -0.30; 95% confidence interval [CI], -0.42 to -0.18; P < 0.001). There were more perforations and emergency corneal grafts in the chlorhexidine arm (24/175, 13.7%) than in the natamycin arm (10/173, 5.8%; P = 0.018, mixed infections included), whereas natamycin-treated cases were less likely to perforate or require an emergency corneal graft, after adjusting for baseline ulcer depth (odds ratio, 0.34; 95% CI, 0.15-0.79; P = 0.013). CONCLUSIONS: Treatment with natamycin is associated with significantly better visual acuity, with fewer adverse events, compared with treatment with chlorhexidine. Natamycin remains the preferred first-line monotherapy treatment for filamentous fungal keratitis.
引用
- Hoffman JJ, Yadav R, Sanyam SD, et al. Topical Chlorhexidine 0.2% versus Topical Natamycin 5% for the Treatment of Fungal Keratitis in Nepal: A Randomized Controlled Noninferiority Trial. Ophthalmology. 2021. PMID: 34896126. doi:10.1016/j.ophtha.2021.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。